Drug intelligence / Profile preview

adrenomedullin + infliximab

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

A combination therapy consisting of adrenomedullin, a bioactive peptide with vasodilating, anti-inflammatory, and mucosal healing properties, and infliximab, a TNF-alpha blocker. This combination has been investigated for treating refractory Crohn's disease, particularly in patients who have developed a loss of response to infliximab monotherapy. In a case report, the addition of adrenomedullin to ongoing infliximab therapy led to rapid symptom remission and significant mucosal healing without the need for steroid therapy.

Targets

CALCRL (Adrenomedullin Receptor)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on adrenomedullin + infliximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adrenomedullin + infliximab.

Explore the full profile